Migraine therapy: Seamlessness between plant-derived and synthetic drugs

Journal of Herbal Pharmacotherapy

Volumn 2, Issue 4, 2002, Pages 3-18

  Fox, Anthony W ^a  

^a EBD Group   (United States)

Author keywords

Butterbur; Ergot; Feverfew; Methysergide; Migraine; Sumatriptan

Indexed keywords

AMINO ACID DERIVATIVE; AMITRIPTYLINE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIMIGRAINE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIHYDROERGOTAMINE; ERGOT ALKALOID; ERGOTAMINE; FENFLURAMINE; HERBACEOUS AGENT; INDOLE DERIVATIVE; METHYSERGIDE; PROPRANOLOL; SEROTONIN 1B AGONIST; SEROTONIN 1D AGONIST; SEROTONIN RECEPTOR; SUMATRIPTAN; TIMOLOL; VALPROATE SEMISODIUM;

ACUTE DISEASE; ARTICLE; CARDIOVASCULAR DISEASE; CLAVICEPS PURPUREA; CLINICAL STUDY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ABSORPTION; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TISSUE LEVEL; DRUG TOLERABILITY; FIBROSIS; HERBAL MEDICINE; HUMAN; METHODOLOGY; MIGRAINE; NAUSEA; PRIORITY JOURNAL; VOMITING;

EID: 0036425995     PISSN: 15228940     EISSN: None     Source Type: Journal    
DOI: 10.1300/J157v02n04_02     Document Type: Article

References (75)

1. Cady RK, Everett KL. Introduction. In: Cady RK, Fox AW, eds., Treating the headache patient. New York: Marcel Dekker Inc., 1994: 1-14.
2. Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. Prevalence and burden of migraine in the United States: Data from the American Migraine Study II. Headache 2001; 41: 646-657.
3. Stewart WF, Lipton RB, Celentano DD, Reed ML. Prevalence of migraine headache in the United States: Relation to age, income, race, and other sociodemographic factors. JAMA 1992; 267: 64-69.
4. Stang PE, Yanagihara PA, Swanson JW. Incidence of migraine headache: A population-based study in Olmsted County, Minnesota. Neurology 1992; 42: 1657-1662.
5. Rasmussen BK. Epidemiology of headache. Cephalalgia 1995; 15: 45-68.
6. Fox AW, Davis RL. Migraine chronobiology. Headache 1998; 38: 436-441.
7. Clouse JC, Osterhaus JT. Healthcare resource use and costs associated with migraine in a managed healthcare setting. Ann Pharmacother 1994; 28: 659-664.
8. Stang PE, Osterhaus JT. Impact of migraine in the United States: Data from the National Health Interview Survey. Headache 1993; 33: 29-35.
9. Osterhaus JT, Gutterman DL, Plachetka JR. Healthcare resource and lost labour costs of migraine headache in the United States. Pharmacoeconomics 1992; 2: 67-76.
10. Wall M, Silberstein SD, Aiken RD. Headache associated with abnormalities in intracranial structure or function: High cerebrospinal fluid pressure headache and brain tumor. In: Silberstein SD, Lipton RB, Dalessio DJ, eds., Wolff's headache and other head pain. Oxford, UK: Oxford University Press, 7th edition, 2001: 393-416.
11. Clemente CD, ed., The anatomy of the human body by Henry Gray FRS. Philadelphia: Lea & Febiger, 30th edition, 1985: 1125, 1158-1169.
12. Graham JR, Wolff HG. Mechanism of migraine headache and action of ergotamine tartrate. Arch Neurol Psych 1938; 39: 737-763.
13. Heyck H. Pathogenesis of migraine. Res Clin Studies Headache 1969; 2: 1-28.
14. Saito K, Markowitz S, Moskowitz MA. Ergot alkaloids block neurogenic extravasation in dura mater: Proposed action in vascular headaches. Ann Neurol 1988; 24: 732-737.
15. Lorenz K. Ergot on cereal grains. CRC Crit Rev Food Sci Nutr 1979; 11: 311-354.
16. Tudzynski P, Correia T, Keller U. Biotechnology and genetics of ergot alkaloids. Appl Microbiol Biotechnol 2001; 57: 593-605.
17. Diekman MA, Green ML. Mycotoxins and reproduction in domestic livestock. J Anim Sci 1992; 70: 1615-1627.
18. Vogt Engeland I, Andresen O, Ropstad E, Kindahl H, Waldeland H, Daskin A, Olav Eik L. Effect of fungal alkaloids on the development of pregnancy and endocrine foetal-placental function in goat. Anim Reprod Sci 1998; 52: 289-302.
19. Bermejo Sanchez E, Rodriguez-Pinella E, Martinez-Frias ML. Use of ergot derivatives during gestation: the ECEMC experience. Reprod Toxicol 1993; 7: 155.
20. Baskett TF. A flux of the reds: Evolution of active management of the third stage of labour. J Roy Soc Med 2000; 93: 489-493.
21. Thoms H. John Stearns and pulvis parturiens. Am J Obstet Gynecol 1931; 22: 418-423.
22. Degroot ANJA, Van Dongen PWJ, Van Roosmalen J. Ergotamine-induced fetal distress: Review of side-effects of ergot alkaloids during pregnancy. Eur J Obstet Gynecol Reprod Biol 1993; 51: 73-77.
23. Brucker MC. Management of the third stage of labor: An evidence-based approach. J Midwif Womens Health 2001; 46: 381-392.
24. Raymond GV. Teratogen update: Ergot and ergotamine. Teratology 1995; 51: 344-347.
25. Zavaleta EG, Fernandez BB, Grove MK, Kaye MD. St. Anthony's fire (ergot-induced leg ischemia)-a case report and review of the literature. Angiology 2001; 52: 349-356.
26. Christopoulos S, Szilagyi A, Kahn SR. St. Anthony's fire. Lancet 2001; 358: 1694.
27. Spanos NP. Ergotism and the Salem witch panic: A critical analysis and an alternative conceptualization. J Hist Behav Sci 1983; 19: 358-369.
28. Peroutka SJ. Drugs effective in the treatment of migraine. In: Hardman JG, Limbird LE, Molinoff P, Ruddon RW, Gilman AG, eds. The pharmacological basis of therapeutics. Ninth edition. New York: McGraw-Hill, 1995: 491, 493, 495-496.
29. Dale HH. On some physiological actions of ergot. J Physiol 1906; 34: 163-206.
30. Horton BT, Peters GA, Blumenthal LS. A new product in the treatment of migraine: A preliminary report. Proc Staff Mtg Mayo Clin 1945; 20: 241-248.
31. Chu D, Owen DAA, Sturmer E. Effects of ergotamine and dihydroergotamine on the resistance and capacitance vessels of skin and skeletal muscle in the cat. Postgrad Med J 1976; 52 (Suppl 1): 32-37.
32. 1 receptor subtypes. Headache 1993; 33: 347-350.
33. McCarthy BG, Peroutka SJ. Comparative neuropharmacology of dihydroergotamine and sumatriptan (GR43175). Headache 1989; 29: 420-422.
34. 1D receptors. Naunyn-Schmiedeburg's Arch Pharmacol 1989; 340: 135-138.
35. 1-like receptor agonist GR43175. Cephalalgia 1989; 9 (Suppl 2): 23-33.
36. Humphrey PPA, Feniuk W, Marriott AS, Taner RJN, Jackson MR, Tucker ML. Preclinical studies on the anti-migraine drug sumatriptan. Eur Neurol 1991; 29: 91-94.
37. Peroutka SJ. 5-hydroxytryptamine receptor sub-types and the pharmacology of migraine. Neurology 1993; 43 (Suppl 3): S34-S38.
38. Cady RK, Wendt JK, Kirchner JR, Sargent JD, Rothrock JF, Skaggs H. Treatment of acute migraine with sumatriptan. JAMA 1991; 265: 2831-2835.
39. Simmons VE, Blakeborough P. The safety profile of sumatriptan. Rev Contemp Pharmacother 1994; 5: 319-328.
40. O'Quinn S, Davis RL, Gutterman DL, Pait GD, Fox AW. Prospective large-scale study of the tolerability of subcutaneous sumatriptan injection for acute treatment of migraine. Cephalalgia 1999; 19: 223-231.
41. Shuhaiber S, Pastuszak A, Schick B, Matsui D, Spivey G, Brochu J, Koren G. Pregnancy outcome following first trimester exposure to sumatriptan. Neurology 1998; 51: 581-588.
42. O'Quinn S, Ephross SA, Williams V, Davis RL, Gutterman DL, Fox AW. Pregnancy and perinatal outcomes in migraineurs using sumatriptan: A prospective study. Arch Gynecol Obstet 1999; 263: 7-12.
43. Fox AW, Chambers CD, Anderson PO, Diamond ML, Spierings ELH. Evidence-based assessment of pregnancy outcome after sumatriptan exposure. Headache 2002; 42: 8-15.
44. 1B/1D agonists. Headache 2000; 40: 521-527.
45. Saxena PR, De Vlaam SG. Role of some biogenic substances in migraine and relevant mechanism in antimigraine action of ergotamine. Studies in experimental animal model for migraine. Headache 1974; 13: 142-146.
46. 3H-spiroperidol. Mol Pharmacol 1979; 687-689.
47. Lance JW, Fine RD, Curran DA. An evaluation of methysergide in the prevention of migraine and other vascular headaches. Med J Austral 1963; 1: 814-818.
48. Silberstein SD. Methysergide. Cephalalgia 1998; 18: 421-435.
49. Khan MA, Herzog CA, St. Peter JV, Hartley GG, Madlon-Kay R, Dick CD, Asinger RW, Vessey JT. The prevalence of cardiac valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetite-suppressant drugs. N Eng J Med 1998; 339: 713-718.
50. Jick H, Vasilakis C, Weinrauch LA, Meier CR, Jick SS, Derby LE. A population-based study of appetite-suppressant drugs and the risk of cardiac valve regurgitation. N Eng J Med 1998; 339: 719-724.
51. Weissman NJ, Tighe JF, Gottdiener JS, Gwynne JT for The Sustained-Release Dexfenfluramine Study Group. An assessment of heart valve abnormalities on obese patients taking dexfenfluramine, sustained-release dexfenfluramine or placebo. N Eng J Med 1998; 339: 725-732.
52. Creutzfeldt W, Stockmann F. Carcinoids and carcinoid syndrome. Am J Med 1987; 82: 4-16.
53. Physicians Desk Reference. Montvale NJ: Medical Economics Co., 54th edition, 2000: 433, 1753, 3251.
54. McChesney JD. Development of herbal medicinals: A pharmaceutical perspective. J Herbal Pharmacother 2001; 1: 51-79. (The quote is taken from p. 66.)
55. Silberstein SD, Saper JR, Freitag F. Migraine diagnosis and treatment. In: Silberstein SD, Lipton RB, Dalessio DJ, eds., Wolff's headache and other head pain. Oxford: Oxford University Press, 2001: 176-199.
56. Physician's Desk Reference, 54th edition. Montvale, New Jersey: Medical Economics Company, 2001: 433, 435, 1753, 3251.
57. Diener HC. Sumatriptan in the treatment of cluster headache. Cephalalgia 2001; 21 (suppl 1): 16-17.
58. Murphy JJ, Heptinstall S, Mitchell JR. Randomised, double-blind, placebo-controlled trial of feverfew in migraine prevention. Lancet 1988; 2: 189-192.
59. Johnson ES, Kadam NP, Hylands DM, Hylands PJ. Efficacy of feverfew as prophylactic treatment of migraine. Br Med J (Clin Res) 1985; 291: 569-573.
60. Grossmann M, Schmidramsl H. An extract of Petasites hybridus is effective in the prophylaxis of migraine. Int J Clin Pharmacol Ther 2000; 38: 430-435.
61. Anderson D, Jenkinson PC, Dewdney RS, Blowers SD, Johnson ES, Kadan NP. Chromosomal aberrations and sister chromatid exchanges in lymphocytes and urine mutagenicity of migraine patients: A comparison of chronic feverfew users and matched non-users. Hum Toxicol 1988; 7: 145-152.
62. Barsby RW, Salan U, Knight DW, Hoult JR. Feverfew and vascular smooth muscle: Extracts from fresh and dried plants show opposing pharmacological profiles, dependent upon sesquiterpene lactone content. Planta Med 1993; 59: 20-25.
63. Fox AW, de Sousa EAJ. "Herbal" remedies and patient protection. Headache 2001; 41: 323-324.
64. Koch V, Danesch U. Response to Fox and de Sousa. Headache 2001; 41: 325-326.
65. Ernst E, Pittler MH. The efficacy and safety of feverfew (Tanacetum parthenium): An update of a systematic review. Public Health Nutr 2000; 3: 509-514.
66. Barnes J, Mills SY, Abbot NC, Willoughby M, Ernst E. Different standards for reporting ADRs to herbal remedies. Br J Clin Pharmacol. 1998; 45: 496-500.
67. Huxtable RJ. The myth of beneficient nature: The risks of herbal preparations. Ann Int Med 1992; 117: 165-166.
68. Ernst E. Harmless herbs? A review of the recent literature. Am J Med 1998; 104: 170-178.
69. Cupp MJ. Herbal remedies: Adverse effects and drug interactions. Am Fam Phys 1999; 59: 1239-1245.
70. Tomlinson B, Chan TYK, Chan JCN, Critchley JAJH, But PPH. Toxicity of complementary therapies: An Eastern perspective. J Clin Pharmacol 2000; 40: 451-456.
71. Nortier JL, Muniz Martinez MC, Schmeiser HH, Arlt VM, Bielier CA, Petein M, Depierreux MF, De Pauw L, Abramowicz D, Vereerstraeten P, Vanherweghem JL. Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia Fangchi). New Eng J Med 2000; 342: 1686-1692.
72. Putnam GP, O'Quinn S, Bolden-Watson CP, Davis RL, Gutterman DL, Fox AW. Migraine polypharmacy and the tolerability of sumatriptan: A large-scale, prospective study. Cephalalgia 1999; 19: 668-675.
73. Andersen JS. Clinical trial designs-made to order. J Biopharm Stat 1996; 6: 515-522.
74. United States Code of Federal Regulations, Title 21, 10: 115, 312: 145, and references therefrom.
75. Kroll DJ. Concerns and needs for research in herbal supplement pharmacotherapy and safety. J Herbal Pharmacother 2001; 1(2): 3-23.